No Data
No Data
BeiGene's Strong Financial and Clinical Prospects Solidify Buy Rating
BeiGene Second Quarter 2024 Earnings: Beats Expectations
Bank of America Securities: Reaffirmed Beigene's "Neutral" rating, with a target price increased to HKD 109.6.
Bank of America Securities released a research report reaffirming its neutral rating on Beigene (06160), and raised the target price from HKD 92.09 to HKD 109.6 due to intense competition and price pressure in the mainland market. The bank raised its sales forecast for the company this year by 10% based on the strong overseas sales of zanubrutinib, and also raised its sales forecast for next year and the year after by 17% and 20%, respectively. At the same time, the bank raised its sales and administrative expense forecasts for the company from this year to 2026, reflecting increased global market promotion activities. The report stated that the company's revenue and product revenue in the second quarter increased by 56% and 66% year-on-year, respectively, mainly from zanubrutinib.
Bocom Intl: Maintains 'buy' rating on Beigene (06160) with a target price of HKD 156.
Bocom Intl has raised the peak global sales forecast for Zejula from 4.4 billion to 5.2 billion.
[Brokerage Focus] BOCOM Intl raised Beigene (06160) target price by 23.8%, indicating that its new wave of innovative achievements is ready to be released.
According to the research report released by Bocom intl, Beigene (06160) achieved a adjusted non-GAAP operating profit of 0.048 billion US dollars (same below) in 2Q24, successfully turned losses into profits (2Q23: 0.193 billion). The bank raised the global sales peak forecast of zebutinib from 4.4 billion to 5.2 billion. The bank pointed out that a new wave of innovative achievements is waiting to be released: 1) Sonrotoclax (Bcl-2) first registration clinical study (global single-arm II phase treatment r/rMCL) has completed enrollment and is expected to complete follow-up, data cleaning and market application declaration in about a year, and the bank expects to
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.